CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Nvidia (NVDA) is down approximately 27.37% since the beginning of 2025 (as of mid-April), and up 26.48% year on year – based on its $98.78 open price on 22 April 2025.
The US Tech 100 is down approximately 5.08% year on year (as of late April 2025), and 11.21% year to date, based on its 23 April 2025 opening price of $9,201.47.
14:22, 25 April 2025
Read our reviews to find out more about us
Read the feedback from our clients, whatever their experience level.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements